ShareThis Page
FDA approves Hysingla painkiller’s abuse deterrent form |

FDA approves Hysingla painkiller’s abuse deterrent form

WASHINGTON — The Food and Drug Administration, which last year faced widespread criticism for approving a powerful painkiller that critics said would be easy to misuse, on Thursday OK’d a new form of the drug that will be hard to crush, break or dissolve — tactics used by people trying to ingest large amounts of a drug quickly by snorting or injecting it.

Hysingla ER, an extended-release drug produced by industry giant Purdue Pharma, is the first abuse deterrent alternative to Zohydro ER. Like Zohydro, it is composed of a dose of pure hydrocodone, the main ingredient in Vicodin.

The pure formulation of hydrocodone is designed to allow long-term treatment of chronic pain without posing the risk of liver damage that occurs with additional ingredients such as acetaminophen.

Hysingla is part of a group of drugs known as opioids, which are effective at relieving serious pain but have played a central role in the nation’s epidemic of deaths linked to painkiller addiction.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.